Cargando…
The Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With COVID-19
Autores principales: | Dai, Cong, Jiang, Min, Huang, Yu-hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940038/ https://www.ncbi.nlm.nih.gov/pubmed/33705746 http://dx.doi.org/10.1053/j.gastro.2021.03.012 |
Ejemplares similares
-
Liver fibrosis and adverse outcomes in COVID-19
por: Huang, Jianmin
Publicado: (2021) -
COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China
por: Dai, Cong, et al.
Publicado: (2021) -
Reply to: “Liver fibrosis and adverse outcomes in COVID-19”
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021) -
Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies
por: Kamal, Faisal, et al.
Publicado: (2021) -
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
por: Kow, Chia Siang, et al.
Publicado: (2020)